Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.

Breakthrough for prostate cancer patients as NHS now offers life-extending drug - The new medication is suitable for patients ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Prostate cancer is the second-most common cancer in men. A new study from Thomas Jefferson University uncovered a new ...

Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

Basel, Switzerland / Munich, Germany, January 26, 2026 - NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that U.S ...

Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...